摘要
临床药师通过参与1例依替巴肽致极重度血小板减少症患者的药学监护,探讨依替巴肽致极重度血小板减少症的特点、机制、预防和处理建议。对经皮冠状动脉介入治疗围术期出现血小板减少者,应根据患者疾病、用药情况及血小板减少的特点,准确判断导致血小板减少的原因,并及时予以正确处理。临床医师及药师应关注依替巴肽引起的血小板减少症,治疗期间加强血小板计数监测和出血反应的监护。
Clinical pharmacists investigated the characteristics,mechanism,prevention and treatment of a patient with severe thrombocytopenia induced by eptifibatide through pharmacological monitoring.For patients with thrombocytopenia during percutaneous coronary intervention,the causes of thrombocytopenia should be accurately determined according to the patient’s condition,medication history and characteristics of thrombocytopenia,and correct treatment should be given in time.Clinician and pharmacists should pay more attention to the thrombocytopenia caused by eptifibatide and strengthen the monitoring of platelet count and bleeding during the treatment.
作者
刘艳
张娟娟
季荣星
LIU Yan;ZHANG Juan-juan;JI Rong-xing(Department of Pharmacy,Henan Provincial Hospital,Zhengzhou 451161)
出处
《中南药学》
CAS
2020年第1期134-137,共4页
Central South Pharmacy
关键词
临床药师
依替巴肽
血小板减少
药学监护
clinical pharmacist
eptifibatide
thrombocytopenia
pharmaceutical care
